Results 211 to 220 of about 18,680 (257)
Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025. [PDF]
Tanabe A +22 more
europepmc +1 more source
Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-meta-iodobenzylguanidine. [PDF]
Sato K +11 more
europepmc +1 more source
MIBG Scintigraphy and Arrhythmic Risk in Myocarditis. [PDF]
Lo Monaco M +7 more
europepmc +1 more source
Ga-68 DOTATATE PET imaging in the management of head and neck paragangliomas: a potential game changer. [PDF]
Alduraibi A +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Polymer‐supported radiopharmaceuticals: [131I]MIBG and [123I]MIBG
Journal of Labelled Compounds and Radiopharmaceuticals, 1999A new method has been developed that produces no-carrier-added [131I]MIBG in ≥90% radiochemical yield and high chemical purity. Isolation and purification are simple involving just filtration and absorption and desorption onto a C18 Sep-Pak™ cartridge.
Duncan H. Hunter, Xizhen Zhu
openaire +2 more sources
Methods, 2011
Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare ...
Voo, S., Bucerius, J., Mottaghy, F.M.
openaire +2 more sources
Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare ...
Voo, S., Bucerius, J., Mottaghy, F.M.
openaire +2 more sources
Medical and Pediatric Oncology, 1997
The fortuitous discovery of a left posterior cervico-mediastinal mass during hospitalization for hemolytic anemia in an 18 month old baby is reported. Metaiodobenzylguanidine (MIBG) uptake suggested a sympathetic tissue origin of the mass despite negative catecholamines excretion, but histopathologic examination revealed a juvenile capillary angioma ...
D, Frappaz +9 more
openaire +2 more sources
The fortuitous discovery of a left posterior cervico-mediastinal mass during hospitalization for hemolytic anemia in an 18 month old baby is reported. Metaiodobenzylguanidine (MIBG) uptake suggested a sympathetic tissue origin of the mass despite negative catecholamines excretion, but histopathologic examination revealed a juvenile capillary angioma ...
D, Frappaz +9 more
openaire +2 more sources

